Please login to the form below

Not currently logged in
Email:
Password:

AZ licensing agreement with Aurobindo

Aurobindo Pharma has announced a licensing and supply agreement with AstraZeneca to supply certain generic products for emerging markets

Aurobindo Pharma has announced a licensing and supply agreement with AstraZeneca (AZ) to supply the Anglo-Swedish drugmaker with certain generic products to be sold in emerging markets.

The generics involved in the agreement include several solid dosage and sterile products and offer therapeutic care in such areas as anti-infectives, as well as covering conditions affecting the cardiovascular system (CVS) and the central nervous system (CNS).

Financial terms of the deal were not disclosed.

India-based Aurobindo manufactures generic pharmaceuticals and active pharmaceutical ingredients, with products marketed in over 125 countries.

This is Aurobindo's second deal with a major global pharmaceutical company to supply drugs for emerging markets following an agreement with Pfizer in 2009.

Speaking on the deal, Kaushik Banerjee, head of branded generics operations at AstraZeneca said "These agreements will enable us to extend the range of branded medicines we are able to offer patients in emerging markets, where we see continued opportunities to grow our business."

Aurobindo chairman P V Ramprasad Reddy said: “Aurobindo's proven track record in building strong, collaborative working relationships is a key driver for these strategic agreements with AstraZeneca which will accelerate our growth plans and support our earnings."

7th September 2010

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
3 Monkeys Zeno

3 Monkeys Zeno is an award winning global creative communications consultancy – home to a collective of creative and strategic...

Latest intelligence

What challenges still face clinical trial recruitment and retention?
Discover the reasons for the current clinical trial recruitment challenges facing pharma and the life sciences industry, and how the search for solutions to the problem continues...
“Fake News” and Credibility in Medical Publishing
Natalie Yeadon from Impetus Digital shares her thoughts on fighting fake news in Pharma and healthcare....
Delivering true value: what does it mean for KAM in cancer care?
Lisa Alderson, Business Development Director at Wilmington Healthcare, explores the challenges that pharma’s KAM teams face in engaging with the NHS and how they must evolve...

Infographics